Megakaryocyte development and platelet production

Varda R. Deutsch[1] and Aaron Tomer[2,3]

[1]The Haematology Institute, Tel Aviv Sourasky Medical Centre, Tel Aviv, [2]Faculty of Health Sciences, Ben Gurion University of the Negev, and [3]Soroka Medical Centre, Blood Bank and Transfusion Medicine, Beer-Sheva, Israel

Summary

Megakaryocytopoiesis involves the commitment of haematopoietic stem cells, and the proliferation, maturation and terminal differentiation of the megakaryocytic progenitors. Circulating levels of thrombopoietin (TPO), the primary growth-factor for the megakaryocyte (MK) lineage, induce concentration–dependent proliferation and maturation of MK progenitors by binding to the c-Mpl receptor and signalling induction. Decreased platelet turnover rates results in increased concentration of free TPO, enabling the compensatory response of marrow MKs to increased platelet production. C-Mpl activity is orchestrated by a complex cascade of signalling molecules that induces the action of specific transcription factors to drive MK proliferation and maturation. Mature MKs form proplatelet projections that are fragmented into circulating particles. Newly developed thrombopoietic agents operating via c-Mpl receptor may prove useful in supporting platelet production in thrombocytopenic state. Herein, we review the regulation of megakaryocytopoiesis and platelet production in normal and disease state, and the new approaches to thrombopoietic therapy.

Keywords: megakaryocytes, megakaryocytopoiesis, thrombopoietin, platelets, platelet production.

Megakaryocyte development

Megakaryocytes (MKs) give rise to circulating platelets (thrombocytes) through commitment of the multipotent stem cell to the MK lineage, proliferation of the progenitors and terminal differentiation of MKs. This process is characterised by DNA endoreduplication, cytoplasmic maturation and expansion, and release of cytoplasmic fragments as circulating platelets. Within the bone marrow (BM), MKs are derived from haematopoietic stem cells (HSCs), which evolve from the multipotential haemangioblast. The haemangioblast gives rise to all blood and blood vessel precursor cells. The HSC gives rise to the early common myeloid progenitor (CMP) that can be cloned as the multi-lineage (granulocyte, erythrocyte, MK and monocyte) colony-forming unit (CFU-GEMM). Erythroid and MK lineages arise from a common MK-erythroid progenitor (MEP) derived from the early CMP (Fig 1). CMP differentiation is orchestrated by molecular signals controlled by regulatory transcription factors (TF). Two major TF involved in CMP differentiation are GATA-1, which drives differentiation of MEP and PU.1, which regulates granulocyte-monocyte precursors (Nutt et al, 2005). The downregulation of PU.1 expression in the CMP is the first event associated with the restriction of differentiation to erythroid and MK lineages (Pang et al, 2005). In response to environmental factors, cytokines and chemokines, the bipotential MEP can develop into the highly proliferative, early MK burst-forming unit (BFU-MK), or the more mature smaller CFU-MK, which both express the CD34 antigen (Briddell et al, 1989). Alternatively, MEP can progress to early and late erythroid progenitors, the BFU-E and CFU-E (Schulze & Shivdasani, 2004). The proliferating diploid MK progenitors (megakaryoblasts) lose their capacity to divide, but retain their ability for DNA replication (endoreduplication) and cytoplasmic maturation.

Megakaryocyte maturation

The hallmarks of MK maturation are endoreduplication (polyploidisation) and expansion of cytoplasmic mass. Mature MKs give rise to circulating platelets by the acquisition of the cytoplasmic structural and functional characteristics necessary for platelet action (Patel et al, 2005; Richardson et al, 2005), reaching cell sizes <50–100 microns in diameter, with ploidy ranges up to 128 N (Tomer et al, 1987, 1988). Early megakaryoblasts have the highest nuclear/cytoplasmic ratio. These immature cells contain elevated RNA levels, prominent ribosomes and rough endoplasmic reticulum, express platelet peroxidase, contain α-granules and dense bodies, and primitive demarcation membrane. As the MK matures, the polyploid nucleus becomes horseshoe-shaped, the cytoplasm expands, and platelet organelles and the demarcation membrane system are amplified (Breton-Gorius & Reyes, 1976). The robust cytoplasmic mass forms proplatelet projections

Fig 1. The megakaryocytopoietic developmental pathway. The figure illustrates the development of megakaryocytes from the haemangioblast (HAB), which gives rise to both vascular and hematopoietic stem cells (HSC). In response to physiological demand, the HSC can produce early progenitor cells of all the haematopoietic lineages, including the common myeloid progenitor (CMP) and the common lymphoid progenitor (CLP). The megakaryocyte progenitor (MKP) is derived from the common megakaryocyte-erythroid progenitor (MEP). The MEP maintains many characteristics of the HSC, which includes the expression of CD34, c-Mpl thrombopoietin receptor, erythropoietin receptor; CD41, glycoprotein IIb/IIIa or αIIβ3-integrin receptor, and is regulated by GATA-1. Pathways leading to platelet production are indicated by solid arrows, other pathways are indicated by dashed arrows. RBC, red blood cell; Gran, granulocyte; Mo, monocyte.

which give rise to *de novo* circulating platelets (Italiano *et al*, 1999; Italiano & Shivdasani, 2003).

While the large polyploid MKs are easily identified, the small MK progenitor and immature MK are difficult to discern. Their identification is facilitated by using antibodies to major platelet membrane glycoproteins (GPs) including the integrin $\alpha_{IIb}\beta_3$ (CD41a or GPIIb/IIIa complex), CD41b (GPIIb), CD61 (GPIIIa), CD42a (GPIX), CD42b (GPIb) and CD51 (αV), as well as against the platelet α-granule proteins, von Willebrand factor (VWF), platelet factor 4 (PF4), β-thromboglobulin (β-TG), fibrinogen, coagulation factor VIII, and factor V (Tomer, 2004). Immature 2–4 N cells produce platelet peroxidase but have no detectable demarcation membrane or platelet α-granules (Breton-Gorius & Reyes, 1976). Anti-CD41 antibodies enable the detection of small 'lymphoid' megakaryoblasts in BM as well in CFU-MK by day 4 or 5 of culture (Mazur *et al*, 1981). Flow cytometry has also been adapted to the direct analysis of human MKs in routine BM aspirates (Tomer *et al*, 1988, 1989). Fluorescence activated cell sorting has enabled the separation of pure viable BM-derived MK populations (>98%) isolated on the basis of lineage markers. These cells were capable of responding to haematopoietic growth factor and synthesising both protein and DNA (Tomer *et al*, 1987). Moreover, flow cytometry has enabled the study of megakaryocytopoiesis in disease states, monitoring of drug effect in humans, and studying the effect of haematopoietic growth factors on megakaryocytopoiesis in humans and primates (Tomer & Harker, 1996; Harker *et al*, 1997; Tomer, 2002).

Recent flow cytometric studies have demonstrated that VWF is strongly expressed by early (2 and 4 N) marrow MKs, enabling their complete resolution from the other marrow cells at a level superior to that achieved with GPIIb/IIIa as a lineage-specific marker (Tomer, 2004).

Early MK differentiation is accompanied by the expression of GPIX, which exists as a heterodimer complex with GPIb and GPV in the platelet membrane. In contrast, platelet GPIV and the thrombospondin (TSP) receptor (CD36) are later differentiation markers (Asch *et al*, 1987). Following activation, the platelet GPIIb/IIIa complex functions as a receptor for four adhesive proteins – fibrinogen, fibronectin, vitronectin and VWF, with GPIb being the major receptor for VWF (Tomer, 2004).

The nuclear endomitotic cell cycle consists of a DNA replication S-phase, an M-phase with multiple pole spindles, aborted anaphase B, aborted cytokinesis and a Gap-phase that enables re-entry into the next S-phase. Cyclin D3, is overexpressed in the G_1-phase of maturing cells and is a key inducer of MK polyploidisation (Ravid *et al*, 2002). Cyclin E may also be important as cyclin E null mice have defective endomitosis of MK and trophoblasts (Geng *et al*, 2003). Aurora-B/AIM-1, the fundamental regulator of mitosis, has normal localisation and expression during prophase and early anaphase but is absent or mislocalised at late anaphase MK (Geddis & Kaushansky, 2004; Zhang *et al*, 2004). Chromosomes segregation is asymmetrical with normal metaphase/anaphase checkpoints (Roy *et al*, 2001). Ploidy classes are identified as

geometric progressions of 2 N (diploid), i.e. 4, 8, 16 N, etc. The ploidy distribution obtained by flow cytometry in fractionated and unfractionated normal human marrow demonstrates 16 N for approximately half of the MK population, 23% of cells being 8 N or lower and 22% 32 N or higher (Tomer *et al*, 1989). The expression of GPIIb/IIIa, GPIIIa, GPIb and CD36 correlates directly with cell size and ploidy, as well as receptor density of GPIIb/IIIa. The mean diameter of the MKs is 37 ± 4 μm (mean ± 1 SD), compared with 14 ± 2 μm of the total marrow cells, ranging from 21 ± 4 μm for 2 N cells to 56 ± 8 μm for 64 N cells (Tomer, 2004). The MK cytoplasmic mass may be calculated as the product of the mean MK cytoplasmic volume and the total number of MKs (Tomer, 2002). By determining the ratio of MKs to nucleated erythroid precursors in marrow preparations by flow cytometric means, the MK mass in patients with primary thrombocytosis was assessed (Tomer & Harker, 1996; Tomer, 2002). Following treatment with anagrelide, both cell frequency and volume decreased towards normal, resulting in decreased MK mass by about half, similar to the decrease in platelet count (Tomer, 2002). This finding of anagrelide effect was recently corroborated by *in vitro* studies (McCarty *et al*, 2006).

Platelet release occurs when the MK cytoplasm is transformed into proplatelets, followed by the release of 2000–5000 new platelets/cell (Long, 1998). Compensatory responses of marrow MKs increase platelet production through an increase in cell proliferation, maturation and release of platelets, as early as 24–48 h after inducing thrombocytopenia. Following thrombocytopheresis and in thrombocytopenias of immune aetiology, the marked increased in MK number and size are notable (Mazur *et al*, 1988; Tomer *et al*, 1988). The normal frequency of human MK in BM is about one in 2000 nucleated cells. However, with compensentory response, the number increases 10-fold (Branehog *et al*, 1975), with an increased proportion of high-ploidy cells seen in BM aspirates (Tomer *et al*, 1989). Reciprocal decreases in MK size, ploidy and volume occur with experimentally induced thrombocytosis (Burstein *et al*, 1979; Jackson *et al*, 1984). These alterations, found in both experimental animals and human subjects, are primarily mediated by thrombopoietin (TPO) (Kaushansky, 2005a).

Regulation of megakaryocytopoiesis

The processes of megakaryocytopoiesis and platelet production occur within a complex BM microenvironment where chemokines, cytokines as well as adhesive interactions play a major role (Avecilla *et al*, 2004). Mechanisms regulating megakaryocytopoiesis operate at the levels of proliferation, differentiation and platelet release (Gewirtz, 1995; Kaushansky, 2003). In addition to the steady state megakaryocytopoiesis, which supplies 10^{11} platelets every day and a new turnover every 8–9 d, MKs also respond to changes in requirements for circulating platelets, increasing more than 10-fold under conditions that demand platelet production (Kaushansky, 2005a).

Thrombopoietin

Thrombopoietin, also known as c-Mpl ligand, is the primary physiological growth factor for the MK lineage, which also plays a central role in the survival and proliferation of HSC (Kaushansky, 2005b, 2006). TPO is the most potent cytokine for stimulating the proliferation and maturation of MK progenitor cells. It stimulates MKs to increase in cell size and ploidy, and to form proplatelet processes that then fragment into single platelets (Kaushansky, 2005a). In baboons, administration of recombinant human (rHu) TPO or polyethylene glycol derivative MK-growth-and-development-factor (PEG-rHuMGDF), produced a log-linear increase in marrow MK mass (cell number multiplied by volume) of up to 6·5-fold that was associated with marked increase in cell ploidy. Concordantly, there was increase in platelet count up to fivefold, reaching peak value after 2–4 weeks of injections (Fig 2). Because MK volume and ploidy attained predictable maximum values simultaneously, MK ploidy is an accurate measure of the Mpl-ligand stimulation of megakaryocytopoiesis (Tomer & Harker, 1996; Harker *et al*, 1997). TPO can also act in synergy with other haematopoietic cytokines and has been utilised effectively to expand human HSC and MK-progenitor cells *in vitro* (Pick *et al*, 2002; Bruno *et al*, 2003; Kaushansky, 2005b; Ivanovic *et al*, 2006).

In platelets, TPO enhances α-granule secretion and aggregation that is induced by thrombin in a phosphoinositide-3 kinase (PI3K)-dependent fashion (Kojima *et al*, 2001). This powerful cytokine also affects mature platelets, reducing the level of ADP, collagen, or thrombin necessary for aggregation (Oda *et al*, 1996; Pasquet *et al*, 2000), and stimulates platelet adhesion (Van Os *et al*, 2003).

Thrombopoietin is encoded by a single human gene, located on chromosome 3q26·3–3q27, which produces a 353 amino acid precursor protein. The mature molecule, composed of 332 amino acids, is acidic and heavily glycosylated. Interestingly, abnormalities (inversion or deletion) at its chromosomal locus are often found in megakaryocytic leukaemia and other myeloproliferative disorders associated with thrombocytosis (Yamamoto *et al*, 2000). Mutations in regulatory regions of the TPO gene, that result in overexpression of TPO and sustained intracellular signalling or disturbed regulation of circulating TPO, cause familial essential thrombocythaemia or familial thrombocytosis (Fig 3B) (Dame & Sutor, 2005; Kaushansky, 2005a). TPO shares high homology with erythropoietin (EPO) in its N-terminal half, reflecting a close evolutionary relationship between their receptor signalling pathways. TPO binds to its receptor on MKs and selectively initiates proliferation, maturation and cytoplasmic delivery of platelets into the circulation (Kaushansky, 1997, 2003). TPO is produced constitutively by the liver and its circulating levels are regulated by the extent of binding to c-Mpl receptors on

(A)

(B)

Fig 2. Effect of *in vivo* administration of megakaryocyte-stimulating factors on marrow megakaryocytes in non-human primates. (A) Ploidy changes in baboons. Left panel: prior to treatment. Middle panel: after treatment with rHu-GM-CSF or IL-6 for 8 d, there is a marked increase in ploidy. Right panel: after treatment with recombinant Human Megakaryocyte Growth and Development Factor (rHuMGDF) for 7 d, the increase in ploidy is more prominent than that observed with GM-CSF. Megakaryocyte ploidy correlates with cell mass (Tomer & Harker, 1996; Tomer, 2004). (B) Effect of rHuMGDF on megakaryocyte mass and platelet production. A concordant increase in both measurements is evident.

circulating platelets and marrow MKs resulting in the elimination of TPO-c-Mpl complexes (Kaushansky, 1997; Scheding *et al*, 2002). This can explain the delayed platelet recovery rate following chemotherapy and platelet transfusions (Slichter, 2004).

Messenger-RNA specific for TPO is also found in the kidney, marrow stroma and other tissues (Sungaran *et al*, 1997); however, its role in megakaryocytopoiesis is unclear. Blood and marrow levels of TPO are usually inversely related to BM MK mass and platelet counts (Kaushansky, 2005a). The plasma levels of TPO in normal state (95 ± 6 pg/l) increase several orders of magnitude in patients with aplastic anaemia or thrombocytopenia secondary to myelosuppression, and decline after platelet transfusions or recovery of haematopoiesis (Kuter & Rosenberg, 1995; Kaushansky, 1997). However, in states of massive platelet destruction, such as immune thrombocytopenic purpura, TPO levels are not as escalated as would be expected from the degree of thrombocytopenia, probably due to the markedly increased platelet turnover rate (Houwerzijl *et al*, 2005). Thus, megakaryocytopoiesis is regulated by plasma levels of unbound TPO, which reflects the balance between constitutive production and rate of destruction that is generally dictated by the overall platelet production. Exceptions to steady state platelet production

occur during essential thrombocythaemia (ET) (Akiyama *et al*, 2005; Harrison, 2005) and in acute inflammation when circulating TPO levels are increased (Cerutti *et al*, 1997; Kaushansky, 1997; Hsu *et al*, 1999) due to enhanced hepatic expression driven by the acute phase protein, interleukin 6 (IL-6) (Wolber *et al*, 2001). Mice in which either TPO or its ligand c-Mpl genes have been knocked out have severe thrombocytopenia with 10–20% residual platelet counts and small numbers of functionally normal MKs (Alexander *et al*, 1996). Their haematopoietic progenitors and their capacity to repopulate haematopoiesis in marrow-deficient mice are markedly reduced (Solberg, 2005). TPO, with its downstream signalling pathways and diverse TFs is, therefore, central but not essential for megakaryocytopoiesis (Kirito & Kaushansky, 2006).

c-Mpl

The TPO receptor (c-Mpl) is predominantly expressed in haematopoietic tissues, haemangioblasts, MKs at all stages of differentiation and platelets. While receptor display is modulated by TPO binding and receptor internalisation, c-Mpl is usually constitutively expressed. TPO avidly binds and activates the c-Mpl receptors on MK and platelets which undergoes conformational changes to initiate signal transduc-

Fig 3. (A) Inherited thrombocytopenia due to disruptions of signalling molecules or transcription factors. Thrombocytopenia of different severities can result from varied inherited genetic mutations. This schema demonstrates the human mutations that are known to occur in the thrombopoietin (TPO) receptor c-Mpl or in transcription factor genes in megakaryocyte progenitor cells. The translated aberrant proteins have different disrupted functions which result in diseases characterised by thrombocytopenia and reduced platelet function. (B) Enhanced megakaryocyte proliferation and thrombocytosis due to aberrations of signalling molecules or transcription factors. Familial thrombocytosis can result from different inherited genetic mutations. This schema demonstrates the human mutations that are known to occur in TPO, its receptor c-Mpl, in the signalling molecule JAK2 or in the transcription factor GATA-1, in megakaryocyte progenitor cells. The translated aberrant proteins have different disrupted functions that result in diseases characterised by enhanced megakaryocyte progenitor proliferation and platelet production.

tion. The Janus kinase (JAK) family kinases constitutively bind to the membrane-proximal cytoplasmic domains of c-Mpl and initiates signalling. The active JAK kinase also phosphorylates tyrosine residues within the receptor itself, as well as downstream signal transducers and activators of transcription (STATs), PI3K, and the mitogen-activated protein kinases (MAPKs). This cascade drives cell survival and proliferation, requires PI3K activation and activates SHP1 and SHIP1 phosphatases and suppressors of cytokine signalling (SOCSs) to limit cell signalling (Kaushansky, 2005b; Solberg, 2005).

Mice in which c-Mpl genes have been knocked out have severe thrombocytopenia, with residual thrombocytopoiesis and small numbers of functionally normal MKs (Alexander *et al*, 1996). Their haematopoietic progenitors are markedly reduced both in cell number and in their capacity to repopulate haematopoiesis in marrow-deficient mice (Solberg, 2005). In humans, elimination of a functional c-Mpl gene (located on chromosome 1p34) or the congenital absence of c-Mpl in children, results in severe thrombocytopenia due to decreased haematopoietic stem and lineage committed progenitor cells (Kaushansky, 2005a). Multiple mutations, including non-sense, frame-shift, splice-site alteration, missense or amino-acid substitutions, have been identified. These mutations result in a total absence of the c-Mpl receptor or functionally defective TPO-binding and/or signalling (van den Oudenrijn *et al*, 2002) with the type of mutation predicting the course of disease (Fig 3A) (King *et al*, 2005; Germeshausen *et al*, 2006). Congenital amegakaryocytic thrombocytopenia

type I BM failure syndrome (CAMT I) in children is characterised by persistently low platelet counts ($<20 \times 10^9$/l) and fast progression into pancytopenia (van den Oudenrijn et al, 2002). Haematopoietic stem-cell transplantation (HSCT) is currently the only curative treatment approach (Steele et al, 2005).

In CAMT type II, patients have delayed development of pancytopenia due to a residual activity of the TPO receptor (Ballmaier et al, 2003; Gandhi et al, 2005a; Germeshausen et al, 2006). In contrast to the c-Mpl null and TPO null mice that maintain haematopoiesis and survive despite the 90% reduction in HSC and circulating platelets, humans with c-Mpl mutations have a lethal disease, which may be due to inherent differences in stem cell regulation and kinetics within the BM vascular niches.

An activating mutation within the transmembrane domain of the c-Mpl has been reported to be associated with familial essential thrombocythaemia (Ding et al, 2004). Interestingly, a c-Mpl polymorphism (Mpl Baltimore), with a single nucleotide substitution unique to individuals of African-American descent (7% heterozygous), is associated with reduced protein expression of Mpl, but a clinical phenotype of thrombocytosis (Moliterno et al, 2004). A similar decrease in c-Mpl receptor on the cell surface is seen in patients with polycythaemia vera (PV) and other myeloproliferative diseases (MPD). Thrombocytosis may therefore be related to the hypersensitivity to cytokines and signalling abnormalities found in these disorders (Kaushansky, 2005a).

Genetic mutations in the *JAK2* gene are prevalent in patients with MPD (Tefferi & Gilliland, 2005). The molecular phenotype involving an activating *JAK2* tyrosine kinase mutation, *JAK2*[V617F] is a somatic point mutation causing the substitution of valine by phenylalanine in the protein product (James et al, 2005). Since a cytokine receptor scaffold is necessary for the transforming and signalling activities of JAK2, mutations can drive proliferative disease only in cells that express the type I cytokine receptors. In PV, the mutational frequency can be as high as 97% and in ET up to 57%, also being expressed in other myeloproliferative disorders (Baxter et al, 2005). At diagnosis, ET patients with the mutation have higher haemoglobin levels, increased white blood cell (WBC) count and an older age, harbouring a survival disadvantage and increased mortality (Wolanskyj et al, 2005). This recent discovery of the molecular basis of ET and other myeloproliferative disorders introduced great optimism for new therapeutic approaches in the near future.

Additional growth factors

While TPO is the main physiological regulator of megakaryocytopoiesis, it is not exclusive in this activity and is thought to function in conjunction with other factors (Kaushansky & Drachman, 2002). Other pleiotropic haematopoietic growth factors that stimulate MK growth alone or in combination with TPO include granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-3, IL-6, IL-11, stem cell factor, FLT ligand, fibroblast growth factor (FGF) and EPO (Tomer et al, 1987, 1988; Broudy & Kaushansky, 1995; Deutsch et al, 1995; Kaushansky et al, 1995; Bruno et al, 2003).

A novel MK growth stimulating peptide has recently been described, which drives robust proliferation of CD34[+] haematopoietic progenitor cells and MK in vitro and MK progenitors in transgenic mice via protein kinase C (PKC) signalling pathways. This unique peptide is derived from the cleavable C-terminus of the stress associated form of acetylcholinesterase (AChE), a molecule known to be involved in the regulation of megakaryocytopoiesis (Long et al, 1982; Lev-Lehman et al, 1997). This readthrough variant (AChE-R), is physiologically functional during stress thrombopoiesis and is currently in preclinical development as a new thrombopoietic factor (Grisaru et al, 2001; Deutsch et al, 2002; Pick et al, 2005).

Negative regulators of megakaryocytopoiesis

Several factors are known to inhibit MK development, including transforming growth factor-β1 (Kuter et al, 1992), PF4 and IL-4 (Han et al, 1991; Zauli & Catani, 1995). Src kinase inhibitors have recently been shown to negatively regulate MK proliferation by inducing MK differentiation and functional platelet-like fragment formation in vitro (Gandhi et al, 2005b; Lannutti et al, 2005). This important discovery may enable new therapeutic modalities for treating thrombocytosis.

Cellular interactions and chemokines

Megakaryocytopoiesis and thrombocytopoiesis require cytokines, chemokines and cellular interactions between HSC, and marrow stromal cells (Avecilla et al, 2004). Stromal-derived factor-1 (SDF-1), of the CXC family, is the key chemokine involved in the retention of haematopoietic precursor cells in the BM. SDF-1 supports megakaryocytopoiesis and homing of HSCs to the BM during foetal development (Wang et al, 1998). SDF-1 is produced locally by the stromal cells, promotes the migration and contact of immature MK with a permissive, endothelial-enriched BM environment (Broxmeyer et al, 2001; Avecilla et al, 2004) in an integrin α4β1-dependent manner (Fox & Kaushansky, 2005). SDF-1 and FGF-4 support platelet production in TPO-/- or mpl-/- mice through interactions of MK progenitors with the BM vascular niche. FGF-4 fortifies the adhesion of MK progenitors to BM endothelial cells, supporting survival and maturation and SDF-1 enhances the movement of MK to the junctions between sinusoidal endothelial cells via VE cadherin, thus driving thrombopoiesis (Avecilla et al, 2004). The SDF-1 receptor, CXCR4, is expressed along the entire MK differentiation pathway from early progenitors to platelets (Wang et al, 1998). Platelet production is enhanced during transendothelial migration of CXCR4[+] MK in response to SDF-1 (Lane et al, 2000). CXCR4 signalling in MK involves both of the serine/threonine MAPKs

MAPK and AKT MAPK pathways, which include extracellular signal-related kinase (MEK) and extracellular signal-regulated protein kinase (ERK)1/ERK2, to regulate cell proliferation and differentiation. The molecular upregulation of the CXC cytokine, CTAP III, in MKs is associated with maturation and, as with other chemokines, is involved in cellular interactions with extracellular matrix and platelet production (Deutsch et al, 2000).

Nuclear transcription factors

Megakaryocyte development and thrombocytopoiesis are controlled by the concerted action of TFs, which form complexes that co-ordinately regulate the chromatin organisation to specifically activate the genes of MK lineage precursors and/or concurrently repress gene expression that support other cell types. Many MK-specific genes are co-regulated by GATA and friend of GATA (FOG) together with acute myeloid leukaemia/runt-related TF 1 (AML/RUNX1) and ETS proteins. Mutations in TF genes result in the translation of aberrant proteins that cause thrombocytopenia or thrombocytosis of various degrees. The inherited changes and disorders that result are summarised in Fig 3A and B. RUNX1 (or AML1) is essential for generation of all definitive haematopoietic lineages. The RUNX1/AML-1 core-binding factor (CBFβ) complex binds the N-terminal transcription activation domain of GATA-1, which enables the programming of MK lineage commitment (Elagib et al, 2003). Chromosomal translocations in the RUNX1 gene is frequently associated with leukaemia, for example the t(8;21) in AML resulting in a dominant-negative RUNX1-ETO fusion protein. Germ line mutations of RUNX1, which cause monoallelic loss of RUNX1 complexes, are found in the autosomal dominant familial platelet disorder (FDP) with multiple platelet defects, reduced c-Mpl and predisposition to AML (Heller et al, 2005).

Megakaryocytic and erythroid lineages, which are derived from a common bipotential progenitor, share many early lineage-restricted TFs (Shivdasani et al, 1997). The zinc-finger protein GATA-1, is the principle TF directing MK development by forming complexes with other TFs (FOG, ETS and RUNX -1) (Tsang et al, 1997). One of the initial events during MK/E lineage restriction is downregulation of PU.1, the main TF responsible for myeloid cell differentiation (Nutt et al, 2005) and upregulation of GATA-1. Reciprocal antagonism of PU.1 and GATA factors balances lineage commitment decisions (Rekhtman et al, 2003; Schulze & Shivdasani, 2004). While the loss of GATA-1 leads to differentiation arrest and apoptosis of erythroid progenitors and accumulation of immature MKs (Gurbuxani et al, 2004), forced GATA-1 expression reprogrammes the common lymphoid and myeloid progenitors to the Meg/E lineage (Iwasaki et al, 2003). GATA-1 possesses a robust MK-specific genetic programme, regulating all stages of MK development (Kaushansky, 2005a). In humans, GATA1 mutations lead to severe diseases involving both erythroid cells and MKs (Schulze et al, 2004; Muntean & Crispino, 2005). A shorter isoform of GATA-1, GATA-1s, is considered to be an early event in the leukemogenesis of Down syndrome (trisomy 21) (Crispino, 2005; Muntean & Crispino, 2005). The association of the N-terminal finger of GATA-1 with its cofactor, the 9-zinc finger FOG-1 is critical for embryonic haematopoiesis and MK development (Shimizu et al, 2004). The clinical significance of the GATA-1/FOG-1 interaction in megakaryocytopoiesis is evident in patients with GATA mutations that interfere with FOG binding, having dyserythropoietic anaemia and severe thrombocytopenia (Muntean & Crispino, 2005) and in X-linked thrombocytopenia due to MK maturation arrest and anaemia (Fig 3) (Schulze & Shivdasani, 2004; Muntean & Crispino, 2005). The Ets family factors reside in close proximity to GATA sequences in MK-specific promoters (Lemarchandel et al, 1993). Friend leukaemia integration-1 (Fli-1), located on chromosome 11q24, is an Ets factor expressed in primary MKs and haemangioblasts. Its loss is associated with the Jacobsen/Paris-Trousseau syndromes (Raslova et al, 2004) and thrombocytopenia with large fused granules within their abnormal blood platelets (Favier et al, 2003).

Nuclear factor erythroid 2 (NF-E2) is a heterodimeric leucine zipper TF that comprises an MK-erythroid specific 45-kDa subunit and a non-lineage specific p18 Maf family subunit which controls terminal MK maturation, proplatelet formation and platelet release (Lecine & Shivdasani, 1998; Schulze & Shivdasani, 2004), by regulating a panoply of MK genes which are crucial elements in the process of platelet production. Little is known about disorders of human platelet production; however, Maf or P45 mutations in mice result in severe impairment of megakaryocytopoiesis (Onodera et al, 2000). NF-E2 deficient mice have profound thrombocytopenia (<5% of normal) with MK maturation arrest and the prominent presence of disorganised internal membranes, reduced granule numbers, and severe platelet deficit and display defective inside-out signalling by the $\alpha_{IIb}\beta_3$ integrin (Shiraga et al, 1999).

The proto-oncogene c-myb, which functions together with p300 as an early mandatory haematopoietic TF, is also a powerful negative regulator of thrombopoiesis in mice (Metcalf et al, 2005). Impairment of its association with the transcriptional coactivator p300 increased numbers of HSCs, MKs and platelets (Sandberg et al, 2005). $Mpl^{-/-}$ mice harbouring mutations in the DNA-binding domain (called plt3) or within the leucine zipper domain (called plt4) of the c-Myb gene, exhibit TPO independent excessive thrombopoiesis (Carpinelli et al, 2004).

Platelet production and release

During MK maturation, internal membrane systems, granules and organelles are assembled in bulk. Platelet production by cytoplasmic fragmentation requires highly structured intricate changes in the MK cytoskeleton and concomitant assembly of anucleate platelets. High ploidy MKs form extensive internal demarcation membrane, which is continuous with the plasma

membrane and serves primarily as a membrane reservoir for the formation of the precursor of cytoplasmic extensions called proplatelets. The open canalicular system, a channelled system for granule release and a dense tubular network, is formed prior to the initiation of proplatelet assembly (Patel *et al*, 2005). Some platelet proteins, such as VWF and fibrinogen receptors, are synthesised and directed to the MK surface membrane while others proteins are conveyed into secretory granules. Individual organelles migrate from the cell body to the proplatelet ends, with approximately 30% of organelles/granules in motion at any given time (Richardson *et al*, 2005). Fibrinogen is taken up by MK from the plasma through endocytosis and/or pinocytosis and selectively transferred to platelet-specific granules.

Quantitative electron microscopic analysis has shown that MKs are located <1 micron away from the marrow sinus wall allowing access of the newly formed platelets to the circulation (Lichtman *et al*, 1978). Because an entire MK may pass through transendothelial apertures of 6 microns diameter, some MKs reach the lungs through the circulation (Tavassoli & Aoki, 1981), which may provide an alternative site for platelet production (Eldor *et al*, 1989; Zucker-Franklin & Philipp, 2000). Nascent platelets contain mitochondria and ribosomal RNA (reticulated platelets), and all the components necessary for platelet function in haemostasis, but do not contain nuclear material (Patel *et al*, 2005).

Currently, there are two models of thrombopoiesis, which are not mutually exclusive. One model proposes platelet assembly and budding off the tips of proplatelets, which operate like assembly lines for platelet production at the end of each proplatelet (Patel *et al*, 2005). The proplatelets extend into sinusoidal spaces, where they detach and fragment into individual platelets, giving rise to about 2000–5000 new platelets (Zucker-Franklin, 1970; Choi *et al*, 1995). The other model of platelet biogenesis proposes that, within the MK cytoplasm, there are preformed territories with internal membranes demarcating prepackaged platelets that are released upon fragmentation of the cytoplasm. This theory is based on electron microscopy analysis of the internal membranes of MKs (Zucker-Franklin & Petursson, 1984; Mori *et al*, 1993). Mature MK, when cultured in contact with subendothelial extracellular matrix, are stimulated to produce platelets by a highly efficient explosive fragmentation of the entire cytoplasm (Caine *et al*, 1986; Eldor *et al*, 1986). *In vivo* and *ex vivo* observations of platelet release from MKs with phase-contrast microscopy strongly support the explosive-fragmentation theory (Deutsch *et al*, 1995; Kosaki, 2005).

Disorders of thrombopoiesis

Disorders of platelets are diverse and can be genetic or acquired. Inherited disorders usually result from genetic mutations within genes that encode regulatory proteins, as mentioned above, or proteins necessary for platelet production, and can have severe clinical results with profound thrombocytopenia and extended bleeding times. May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, Alport syndrome, and Epstein syndrome are related to mutations in the MYH9 non-muscle myosin heavy chain IIA gene, which encodes the sole myosin isoform expressed in platelets and neutrophils (Balduini *et al*, 2002). The defect in myosin causes altered cytoskeletal dynamics resulting in macro-thrombocytopenia. Bernard–Soulier syndrome is an autosomal dominant disorder characterised by a prolonged bleeding time, macrothrombocytopenia, defective prothrombin consumption and poor platelet adhesion. The dysfunction is due to the absent or deficient expression of the GPIb/IX/V complex, which forms the VWF receptor on the platelet surface (Caen & Rosa, 1995). Several mutations within the genes that encode GPIbα, GPV, or GPIX have been identified (Patel *et al*, 2005). Gray platelet syndrome is another autosomal dominant disease characterised by macrothrombocytopenia with absence of α-granules. This abnormality is due to inadequate packaging of VWF and fibrinogen within the α-granules, which fail to mature during MK differentiation. The clinical and molecular heterogeneity in this syndrome has been recently reviewed (Nurden & Nurden, 2006).

Clinical use of thrombopoietic agents

It was expected that the physiologically powerful stimulators of thrombocytopoiesis, rHuTPO, or the truncated cloned rHuMGDF, would be effective in patients with thrombocytopenia responsive to exogenous stimulation of platelet production. Although in non-human primates the administration of rHuTPO or PEG-rHuMGDF resulted in marked responses (Tomer & Harker, 1996; Harker *et al*, 1997) (Fig 2), in human trials performed with the truncated PEG-rHuMDGF, cross-reacting neutralising antibody to endogenous TPO developed, which led to cessation of the trials (Basser, 2002; Solberg, 2005). In addition, although rHu-TPO facilitated the collection of platelets in normal donors and patients for transfusion purposes (Kuter *et al*, 2001) in thrombocytopenic patients, there was no positive effect on platelet recovery following aggressive chemotherapy (Kaushansky, 1995). The administration of rHuTPO before or after stem cell transplantation and myeloablative therapy had no impact on the duration of severe thrombocytopenia, nor did it reduce the requirement for platelet transfusions either post-transplant or in AML patients (Bernstein *et al*, 2002; Nash *et al*, 2002; Schuster *et al*, 2002). The failure of escalated TPO levels to stimulate platelet production may be related to the paucity of MK progenitor population (Scheding *et al*, 2002; Vadhan-Raj *et al*, 2005). In a recent phase I study by the Children's Oncology Group, Children's National Medical Center, children with solid tumours received rHuTPO with granulocyte colony-stimulating factor (G-CSF) after combination chemotherapy. The rHuTPO was well tolerated and various doses resulted in a median time to platelet recovery ($>100 \times 10^9$/l) of 22–25 d. Time to haematological recovery and median number of platelet transfusions was somewhat improved compared with historical controls receiving combi-

nation chemotherapy with G-CSF (Angiolillo et al, 2005). A recent review of the use of thombopoietic factors in chronic BM failure states, suggests that although the temporal pace of response appears to be relatively slow, durable responses can be achieved in patients given thrombopoietic factors for extended periods of time (Kurzrock, 2005). Thus, TPO may prove useful in thrombocytopenic states where stem cells have not been severely depleted and the marrow microenvironment can support thrombopoietic activity.

Human trials have been performed with IL-6 and IL-11. IL-6 is a pleiotropic cytokine with potent thrombopoietic activity (Stahl & Zucker-Franklin, 1993) and its administration to humans markedly increased platelet counts (Hoffman, 1989) and accelerated platelet recovery post autologous peripheral blood stem cell transplantation (Nagler et al, 1995). Unfortunately, IL-6 administration involved severe toxicities (Kurzrock, 2005). The multilineage cytokine IL-11 has been shown to attenuate chemotherapy-induced thrombocytopenia (Kurzrock, 2005) and the administration of low-dose IL-11 raised platelet counts without significant toxicity in selected patients with BM failure (Kurzrock et al, 2001). Currently, IL-11 (Neumega) is the only clinically approved drug for treating thrombocytopenia (Orazi et al, 1996), but has limited effects with no clear cost benefit over platelet transfusions (Cantor et al, 2003; Kurzrock, 2005).

Currently, exciting studies with the new thrombopoietic agents have invigorated the field, with positive results reported in idiopathic thrombocytopenic purpura and other disorders (Solberg, 2005). AMG531 is an engineered peptibody with no sequence homology to TPO. It is composed of a recombinant protein carrier Fc domain linked to multiple Mpl-binding domains and has similar effects on megakaryocytopoiesis to that of TPO. Kuter (2005) described a phase II clinical trial of 21 immune thrombocytopenic purpura (ITP) patients treated with AMG531 for 6 weeks with platelet counts that increased in most patients to greater than 50×10^9/l. The recent safety profile of AMG531 summarises two phase 1 studies in a total of 56 healthy volunteers and three phase 2 studies, with the option to continue in an open-label extension study, in a total of 57 patients with ITP. No clinically important events or detectable neutralising antibodies were reported. However, across the phase II studies, three patients experienced worsening of thrombocytopenia, one patient had elevated lactate dehydrogenase and one patient, diffuse reticulin formation in the BM (Stepan et al, 2005).

Another phase I trial with a novel, pegylated TPO-mimetic peptide (peg-TPOmp), was described by Cerneus et al (2005) in which 40 volunteers were randomised to receive this TPO receptor agonist or placebo as a single i.v. bolus. Platelet counts increased dose-dependently, reaching peak levels at day 10–12, and returned to baseline within 3–4 weeks, with mean peak platelet levels ranging from 315×10^9 to 685×10^9/l, and increments of 1·4-fold to 3·2-fold. Platelet function was not different between the treatments. No serious adverse events and no antibodies against peg-TPOmp were detected.

A minibody agonist of the c-Mpl was recently used in a novel therapeutic approach to treat thrombocytopenia (Orita et al, 2005). IgG antibodies were engineered against the TPO receptor with absent or very weak agonist activity, to be agonist minibodies, which include diabody or single chain (Fv)2 [sc(Fv)2] as strong as the natural ligand. Two minibodies were successfully constructed to bind and activate two types of dysfunctional mutant of Mpl receptor that cause CAMT. This conversion of biological activities by designing minibodies can be widely applicable in the future to generate agonist minibodies for other clinical applications.

Three new synthetic c-Mpl agonists under preclinical development have recently been described. One is an orally active, nonpeptidyl TPO receptor agonist, YM477 (Suzuki et al, 2005). Its effect was examined in human platelet-producing non-obese diabetic severe combined immunodeficient mice in which human HSCs were transplanted. Oral administration of YM477 dose-dependently increased the number of human platelets produced by these mice, reaching an increase of about 3·0-fold on day 14. The other synthetic c-Mpl agonist, NIP-004, induced the proliferation of various TPO-responsive cell lines, primary human haematopoietic progenitor cells and human thrombocytopoiesis in a xeno-transplant animal model, showing 1·5-fold increase of HuCD45$^+$CD34$^+$CD41a$^+$ megakaryoblasts and threefold increase of HuCD41a$^+$ 128 N matured polyploid MKs in murine BM. NIP-004 increased the circulating HuCD41a$^+$ platelets by sixfold (Nakamura et al, 2006). The efficacy and safety of these molecules in clinical settings has yet to be determined. SB-497115 is a non-peptidyl TpoR agonist that is being developed by GlaxoSmithKline to treat thrombocytopenia. Data from a phase I study in healthy volunteers, show that SB-497115 increased platelet counts in a dose-dependent fashion when administered orally (Jenkins et al, 2004). Patients are currently being recruited in phase II clinical trials.

In conclusion, the recently acquired knowledge of the molecular mechanisms that regulate megakaryocytopoiesis and platelet production, together with the new developments in the generation and availability of various thrombopoietic agents, provide a strong basis for optimism in the future therapy of thrombocytopenic states.

Acknowledgements

References

Akiyama, T., Matsunaga, T., Terui, T., Miyanishi, K., Tanaka, I, Sato, T., Kuroda, H., Takimoto, R., Takayama, T., Kato, J., Yamauchi, N., Kogawa, K., Sakamaki, S., Hirayama, Y., Kohda, K. & Niitsu, Y.

(2005) Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis. *Leukemia*, **19**, 1558–1566.

Alexander, W.S., Roberts, A.W., Nicola, N.A., Li, R. & Metcalf, D. (1996) Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. *Blood*, **87**, 2162–2170.

Angiolillo, A.L., Davenport, V., Bonilla, M.A., van de Ven, C., Ayello, J., Militano, O., Miller, L.L., Krailo, M., Reaman, G. & Cairo, M.S. (2005) A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. *Clinical Cancer Research*, **11**, 2644–2650.

Asch, A.S., Barnwell, J., Silverstein, R.L. & Nachman, R.L. (1987) Isolation of the thrombospondin membrane receptor. *Journal of Clinical Investigation*, **79**, 1054–1061.

Avecilla, S.T., Hattori, K., Heissig, B., Tejada, R., Liao, F., Shido, K., Jin, D.K., Dias, S., Zhang, F., Hartman, T.E., Hackett, N.R., Crystal, R.G., Witte, L., Hicklin, D.J., Bohlen, P., Eaton, D., Lyden, D., de Sauvage, F. & Rafii, S. (2004) Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. *Nature Medicine*, **10**, 64–71.

Balduini, C.L., Iolascon, A. & Savoia, A. (2002) Inherited thrombocytopenias: from genes to therapy. *Haematologica*, **87**, 860–880.

Ballmaier, M., Germeshausen, M., Krukemeier, S. & Welte, K. (2003) Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. *Annals of the New York Academy of Sciences*, **996**, 17–25

Basser, R. (2002) The impact of thrombopoietin on clinical practice. *Current Pharmacy Design*, **8**, 369–377.

Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet*, **365**, 1054–1061.

Bernstein, S.H., Jusko, W.J., Krzyzanski, W., Nichol, J. & Wetzler, M. (2002) Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy. *Journal of Clinical Pharmacology*, **42**, 501–511.

Branehog, I., Ridell, B., Swolin, B. & Weinfeld, A. (1975) Megakaryocyte quantifications in relation to thrombokinetics in primary thrombocythaemia and allied diseases. *Scandinavian Journal of Haematology*, **15**, 321–332.

Breton-Gorius, J. & Reyes, F. (1976) Ultrastructure of human bone marrow cell maturation. *International Review of Cytology*, **46**, 251–321.

Briddell, R.A., Brandt, J.E., Straneva, J.E., Srour, E.F. & Hoffman, R. (1989) Characterization of the human burst-forming unit-megakaryocyte. *Blood*, **74**, 145–151.

Broudy, V.C. & Kaushansky, K. (1995) Thrombopoietin, the c-mpl ligand, is a major regulator of platelet production. *Journal of Leukocyte Biology*, **57**, 719–725.

Broxmeyer, H.E., Youn, B.S., Kim, C., Hangoc, G., Cooper, S. & Mantel, C. (2001) Chemokine regulation of hematopoiesis and the involvement of pertussis toxin-sensitive G alpha i proteins. *Annals of the New York Academy of Sciences*, **938**, 117–127 discussion 127–118.

Bruno, S., Gunetti, M., Gammaitoni, L., Dane, A., Cavalloni, G., Sanavio, F., Fagioli, F., Aglietta, M. & Piacibello, W. (2003) In vitro and in vivo megakaryocyte differentiation of fresh and ex-vivo expanded cord blood cells: rapid and transient megakaryocyte reconstitution. *Haematologica*, **88**, 379–387.

Burstein, S.A., Adamson, J.W., Thorning, D. & Harker, L.A. (1979) Characteristics of murine megakaryocytic colonies in vitro. *Blood*, **54**, 169–179.

Caen, J.P. & Rosa, J.P. (1995) Platelet-vessel wall interaction: from the bedside to molecules. *Thrombosis and Haemostasis*, **74**, 18–24.

Caine, Y.G., Vlodavsky, I., Hersh, M., Polliack, A., Gurfel, D., Or, R., Levine, R.F. & Eldor, A. (1986) Adhesion, spreading and fragmentation of human megakaryocytes exposed to subendothelial extracellular matrix: a scanning electron microscopy study. *Scandinavian Electron Microscopy*, **3**, 1087–1094.

Cantor, S.B., Elting, L.S., Hudson, Jr, D.V. & Rubenstein, E.B. (2003) Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. *Cancer*, **97**, 3099–3106.

Carpinelli, M.R., Hilton, D.J., Metcalf, D., Antonchuk, J.L., Hyland, C.D., Mifsud, S.L., Di Rago, L., Hilton, A.A., Willson, T.A., Roberts, A.W., Ramsay, R.G., Nicola, N.A. & Alexander, W.S. (2004) Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. *Proceedings of the National Academy of Sciences of the United States of America*, **101**, 6553–6558.

Cerneus, D., Brown, K., Harris, R., End, D., Molloy, C., Yurkow, E., Koblish, H., Franks, C., Moolenaar, M. & Burggraaf, K. (2005) Stimulation of platelet production in healthy volunteers by a novel pegylated peptide based thrombopoietin (TPO) receptor antagonist. *Blood*, **106**, 1249a.

Cerutti, A., Custodi, P., Duranti, M., Noris, P. & Balduini, C.L. (1997) Thrombopoietin levels in patients with primary and reactive thrombocytosis. *British Journal of Haematology*, **99**, 281–284.

Choi, E.S., Nichol, J.L., Hokom, M.M., Hornkohl, A.C. & Hunt, P. (1995) Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. *Blood*, **85**, 402–413.

Crispino, J.D. (2005) GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. *Pediatr Blood Cancer*, **1**, 40–44.

Dame, C. & Sutor, A.H. (2005) Primary and secondary thrombocytosis in childhood. *British Journal of Haematology*, **129**, 165–177.

Deutsch, V.R., Olson, T.A., Nagler, A., Slavin, S., Levine, R.F. & Eldor, A. (1995) The response of cord blood megakaryocyte progenitors to IL-3, IL-6 and aplastic canine serum varies with gestational age. *British Journal of Haematology*, **89**, 8–16.

Deutsch, V., Bitan, M., Friedmann, Y., Eldor, A. & Vlodavsky, I. (2000) Megakaryocyte maturation is associated with expression of the CXC chemokine connective tissue-activating peptide CTAP III. *British Journal of Haematology*, **111**, 1180–1189.

Deutsch, V.R., Pick, M., Perry, C., Grisaru, D., Hemo, Y., Golan-Hadari, D., Grant, A., Eldor, A. & Soreq, H. (2002) The stress-associated acetylcholinesterase variant AChE-R is expressed in human CD34(+) hematopoietic progenitors and its C-terminal peptide ARP promotes their proliferation. *Experimental Hematology*, **30**, 1153–1161.

Ding, J., Komatsu, H., Wakita, A., Kato-Uranishi, M., Ito, M., Satoh, A., Tsuboi, K., Nitta, M., Miyazaki, H., Iida, S. & Ueda, R. (2004)

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. *Blood*, 103, 4198–4200.

Elagib, K.E., Racke, F.K., Mogass, M., Khetawat, R., Delehanty, L.L. & Goldfarb, A.N. (2003) RUNX1 and GATA-1 coexpression and co-operation in megakaryocytic differentiation. *Blood*, 101, 4333–4341.

Eldor, A., Levine, R.F., Caine, Y.G., HyAm, E. & Vlodavsky, I. (1986) Megakaryocyte interaction with the subendothelial extracellular matrix. *Progress in Clinical and Biological Research*, 215, 399–404.

Eldor, A., Vlodavsky, I., Deutsch, V. & Levine, R.F. (1989) Megakaryocyte function and dysfunction. *Baillieres Clinical Haematology*, 2, 543–568.

Favier, R., Jondeau, K., Boutard, P., Grossfeld, P., Reinert, P., Jones, C., Bertoni, F. & Cramer, E.M. (2003) Paris-Trousseau syndrome: clinical, hematological, molecular data of ten new cases. *Thrombosis and Haemostasis*, 90, 893–897.

Fox, N.E. & Kaushansky, K. (2005) Engagement of integrin alpha4-beta1 enhances thrombopoietin-induced megakaryopoiesis. *Experimental Hematology*, 33, 94–99.

Gandhi, M.J., Pendergrass, T.W., Cummings, C.C., Ihara, K., Blau, C.A. & Drachman, J.G. (2005a) Congenital amegakaryocytic thrombocytopenia in three siblings: molecular analysis of atypical clinical presentation. *Experimental Hematology*, 33, 1215–1221.

Gandhi, M.J., Drachman, J.G., Reems, J.A., Thorning, D. & Lannutti, B.J. (2005b) A novel strategy for generating platelet-like fragments from megakaryocytic cell lines and human progenitor cells. *Blood Cells, Molecules, and Diseases*, 35, 70–73.

Geddis, A.E. & Kaushansky, K. (2004) Megakaryocytes express functional Aurora-B kinase in endomitosis. *Blood*, 104, 1017–1024.

Geng, Y., Yu, Q., Sicinska, E., Das, M., Schneider, J.E., Bhattacharya, S., Rideout, W.M., Bronson, R.T., Gardner, H. & Sicinski, P. (2003) Cyclin E ablation in the mouse. *Cell*, 114, 431–443.

Germeshausen, M., Ballmaier, M. & Welte, K. (2006) MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. *Human Mutation*, 27, 296.

Gewirtz, A.M. (1995) Megakaryocytopoiesis: the state of the art. *Thrombosis and Haemostasis*, 74, 204–209.

Grisaru, D., Deutsch, V., Shapira, M., Pick, M., Sternfeld, M., Melamed-Book, N., Kaufer, D., Galyam, N., Gait, M.J., Owen, D., Lessing, J.B., Eldor, A. & Soreq, H. (2001) ARP, a peptide derived from the stress-associated acetylcholinesterase variant, has hematopoietic growth promoting activities. *Molecular Medicine*, 7, 93–105.

Gurbuxani, S., Vyas, P. & Crispino, J.D. (2004) Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. *Blood*, 103, 399–406.

Han, Z.C., Bellucci, S. & Caen, J.P. (1991) Megakaryocytopoiesis: characterization and regulation in normal and pathologic states. *International Journal of Hematology*, 54, 3–14.

Harker, L.A., Marzec, U.M., Kelly, A.B., Cheung, E., Tomer, A., Nichol, J.L., Hanson, S.R. & Stead, R.B. (1997) Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. *Blood*, 89, 155–165.

Harrison, C.N. (2005) Essential thrombocythaemia: challenges and evidence-based management. *British Journal of Haematology*, 130, 153–165.

Heller, P.G., Glembotsky, A.C., Gandhi, M.J., Cummings, C.L., Pirola, C.J., Marta, R.F., Kornblihtt, L.I., Drachman, J.G. & Molinas, F.C. (2005) Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. *Blood*, 105, 4664–4670.

Hoffman, R. (1989) Regulation of megakaryocytopoiesis. *Blood*, 74, 1196–1212.

Houwerzijl, E.J., Louwes, H., Esselink, M.T., Smit, J.W., Vellenga, E. & de Wolf, J.T. (2005) Increased glycocalicin index and normal thrombopoietin levels in patients with idiopathic thrombocytopenic purpura with a decreased rate of platelet production. *Haematologica*, 90, 710–711.

Hsu, H.C., Tsai, W.H., Jiang, M.L., Ho, C.H., Hsu, M.L., Ho, C.K. & Wang, S.Y. (1999) Circulating levels of thrombopoietic and in-flammatory cytokines in patients with clonal and reactive thrombocytosis. *Journal of Laboratory and Clinical Medicine*, 134, 392–397.

Italiano, J.E., Jr & Shivdasani, R.A. (2003) Megakaryocytes and beyond: the birth of platelets. *Journal of Thrombosis and Haemostasis*, 1, 1174–1182.

Italiano, J.E., Jr, Lecine, P., Shivdasani, R.A. & Hartwig, J.H. (1999) Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. *Journal of Cell Biology*, 147, 1299–1312.

Ivanovic, Z., Duchez, P., Dazey, B., Hermitte, F., Lamrissi-Garcia, I., Mazurier, F., Praloran, V., Reiffers, J., Vezon, G. & Boiron, J.M. (2006) A clinical-scale expansion of mobilized CD34+ hematopoietic stem and progenitor cells by use of a new serum-free medium. *Transfusion*, 46, 126–131.

Iwasaki, H., Mizuno, S., Wells, R.A., Cantor, A.B., Watanabe, S. & Akashi, K. (2003) GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages. *Immunity*, 19, 451–462.

Jackson, C.W., Brown, L.K., Somerville, B.C., Lyles, S.A. & Look, A.T. (1984) Two-color flow cytometric measurement of DNA distributions of rat megakaryocytes in unfixed, unfractionated marrow cell suspensions. *Blood*, 63, 768–778.

James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature*, 434, 1144–1148.

Jenkins, J., Nicholl, R., Williams, D., Baidoo, C., Phillips, J., Deng, Y., Kitchen, V. & Erickson-Miller, C. (2004) An oral, non-petide, small molecule thrombopoietin receptor agonist increases platelet counts in healthy subjects. *Blood*, 104, 2916a.

Kaushansky, K. (1995) Thrombopoietin: the primary regulator of platelet production. *Blood*, 86, 419–431.

Kaushansky, K. (1997) Thrombopoietin: basic biology and clinical promise. *Leukemia*, 11 (Suppl. 3), 426–427.

Kaushansky, K. (2003) Thrombopoietin: a tool for understanding thrombopoiesis. *Journal of Thrombosis and Haemostasis*, 1, 1587–1592.

Kaushansky, K. (2005a) The molecular mechanisms that control thrombopoiesis. *Journal of Clinical Investigation*, 115, 3339–3347.

Kaushansky, K. (2005b) Thrombopoietin and the hematopoietic stem cell. *Annals of the New York Academy of Sciences*, 1044, 139–141.

Kaushansky, K. (2006) Lineage-specific hematopoietic growth factors. *New England Journal of Medicine*, 354, 2034–2045.

Kaushansky, K. & Drachman, J.G. (2002) The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. *Oncogene*, **21**, 3359–3367.

Kaushansky, K., Broudy, V.C., Lin, N., Jorgensen, M.J., McCarty, J., Fox, N., Zucker-Franklin, D. & Lofton-Day, C. (1995) Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. *Proceedings of the National Academy of Sciences of the United States of America*, **92**, 3234–3238.

King, S., Germeshausen, M., Strauss, G., Welte, K. & Ballmaier, M. (2005) Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. *British Journal of Haematology*, **131**, 636–644.

Kirito, K. & Kaushansky, K. (2006) Transcriptional regulation of megakaryopoiesis: thrombopoietin signaling and nuclear factors. *Current Opinion of Hematology*, **13**, 151–156.

Kojima, H., Shinagawa, A., Shimizu, S., Kanada, H., Hibi, M., Hirano, T. & Nagasawa, T. (2001) Role of phosphatidylinositol-3 kinase and its association with Gab1 in thrombopoietin-mediated up-regulation of platelet function. *Experimental Hematology*, **29**, 616–622.

Kosaki, G. (2005) In vivo platelet production from mature megakaryocytes: does platelet release occur via proplatelets? *International Journal of Hematology*, **81**, 208–219.

Kurzrock, R. (2005) Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited. *Clinical Cancer Research*, **11**, 1361–1367.

Kurzrock, R., Cortes, J., Thomas, D.A., Jeha, S., Pilat, S. & Talpaz, M. (2001) Pilot study of low-dose interleukin-11 in patients with bone marrow failure. *Journal of Clinical Oncology*, **19**, 4165–4172.

Kuter, D.J. (2005) The promise of thrombopoietins in the treatment of ITP. *Clinical Advanced Hematology and Oncology*, **3**, 464–466.

Kuter, D.J. & Rosenberg, R.D. (1995) The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. *Blood*, **85**, 2720–2730.

Kuter, D.J., Gminski, D.M. & Rosenberg, R.D. (1992) Transforming growth factor beta inhibits megakaryocyte growth and endomitosis. *Blood*, **7**, 619–626

Kuter, D.J., Goodnough, L.T., Romo, J., DiPersio, J., Peterson, R., Tomita, D., Sheridan, W. & McCullough, J. (2001) Thrombopoietin therapy increases platelet yields in healthy platelet donors. *Blood*, **98**, 1339–1345.

Lane, W.J., Dias, S., Hattori, K., Heissig, B., Choy, M., Rabbany, S.Y., Wood, J., Moore, M.A. & Rafii, S. (2000) Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. *Blood*, **96**, 4152–4159.

Lannutti, B.J., Blake, N., Gandhi, M.J., Reems, J.A. & Drachman, J.G. (2005) Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656. *Blood*, **105**, 3875–3878.

Lecine, P. & Shivdasani, R.A. (1998) Cellular and molecular biology of megakaryocyte differentiation in the absence of lineage-restricted transcription factors. *Stem Cells*, **16** (Suppl. 2), 91–95.

Lemarchandel, V., Ghysdael, J., Mignotte, V., Rahuel, C. & Romeo, P.H. (1993) GATA and Ets cis-acting sequences mediate megakaryocyte-specific expression. *Molecular and Cellular Biology*, **13**, 668–676.

Lev-Lehman, E., Deutsch, V., Eldor, A. & Soreq, H. (1997) Immature human megakaryocytes produce nuclear-associated acetylcholinesterase. *Blood*, **89**, 3644–3653.

Lichtman, M.A., Chamberlain, J.K., Simon, W. & Santillo, P.A. (1978) Parasinusoidal location of megakaryocytes in marrow: a determinant of platelet release. *American Journal of Hematology*, **4**, 303–312.

Long, M.W. (1998) Megakaryocyte differentiation events. *Seminars in Hematology*, **35**, 192–199.

Long, M.W., Williams, N. & McDonald, T.P. (1982) Immature megakaryocytes in the mouse: in vitro relationship to megakaryocyte progenitor cells and mature megakaryocytes. *Journal of Cellular Physiology*, **112**, 339–344.

Mazur, E.M., Hoffman, R., Chasis, J., Marchesi, S. & Bruno, E. (1981) Immunofluorescent identification of human megakaryocyte colonies using an antiplatelet glycoprotein antiserum. *Blood*, **57**, 277–286.

Mazur, E.M., Lindquist, D.L., de Alarcon, P.A. & Cohen, J.L. (1988) Evaluation of bone marrow megakaryocyte ploidy distributions in persons with normal and abnormal platelet counts. *Journal of Laboratory and Clinical Medicine*, **111**, 194–202.

McCarty, J.M., Melone, P.D., Simanis, J.P., Kanamori, D., Dessypris, E.N. & Warshamana-Greene, G.S. (2006) A preliminary investigation into the action of anagrelide: thrombopoietin-c-Mpl receptor interactions. *Experimental Hematology*, **34**, 87–96.

Metcalf, D., Carpinelli, M.R., Hyland, C., Mifsud, S., Dirago, L., Nicola, N.A., Hilton, D.J. & Alexander, W.S. (2005) Anomalous megakaryocytopoiesis in mice with mutations in the c-Myb gene. *Blood*, **105**, 3480–3487.

Moliterno, A.R., Williams, D.M., Gutierrez-Alamillo, L.I., Salvatori, R., Ingersoll, R.G. & Spivak, J.L. (2004) Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. *Proceedings of the National Academy of Sciences of the United States of America*, **101**, 11444–11447.

Mori, M., Tsuchiyama, J. & Okada, S. (1993) Proliferation, migration and platelet release by megakaryocytes in long-term bone marrow culture in collagen gel. *Cell Structure and Function*, **18**, 409–417.

Muntean, A.G. & Crispino, J.D. (2005) Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. *Blood*, **106**, 1223–1231.

Nagler, A., Deutsch, V.R., Varadi, G., Pick, M., Eldor, A. & Slavin, S. (1995) Recombinant human interleukin-6 accelerates in-vitro megakaryocytopoiesis and platelet recovery post autologous peripheral blood stem cell transplantation. *Leukemia and Lymphoma*, **19**, 343–349.

Nakamura, T., Miyakawa, Y., Miyamura, A., Yamane, A., Suzuki, H., Ito, M., Ohnishi, Y., Ishiwata, N., Ikeda, Y. & Tsuruzoe, N. (2006) A novel non-peptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. *Blood*, **107**, 4300–4307.

Nash, R.A., Takatu, A., Feng, Z., Slichter, S., Abrams, K., Espino, G., Gass, M.J., Georges, G.E., McSweeney, P.A., Shulman, H.M. & Storb, R. (2002) Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: low-dose TBI does not prevent sensitization. *Biol Blood Marrow Transplant*, **8**, 360–367.

Nurden, A.T. & Nurden, P. (2006) The gray platelet syndrome: clinical spectrum of the disease. *Blood Reviews*, **20**, 83–92.

Nutt, S.L., Metcalf, D., D'Amico, A., Polli, M. & Wu, L. (2005) Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. *Journal of Experimental Medicine*, **201**, 221–231.

Oda, A., Miyakawa, Y., Druker, B.J., Ozaki, K., Yabusaki, K., Shirasawa, Y., Handa, M., Kato, T., Miyazaki, H., Shimosaka, A. & Ikeda, Y.

(1996) Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. *Blood*, **87**, 4664–4670.

Onodera, K., Shavit, J.A., Motohashi, H., Yamamoto, M. & Engel, J.D. (2000) Perinatal synthetic lethality and hematopoietic defects in compound mafG::mafK mutant mice. *EMBO Journal*, **19**, 1335–1345.

Orazi, A., Cooper, R.J., Tong, J., Gordon, M.S., Battiato, L., Sledge, Jr, G.W., Kaye, J.A., Kahsai, M. & Hoffman, R. (1996) Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow. *Experimental Hematology*, **24**, 1289–1297.

Orita, T., Tsunoda, H., Yabuta, N., Nakano, K., Yoshino, T., Hirata, Y., Ohtomo, T., Nezu, J., Sakumoto, H., Ono, K., Saito, M., Kumagai, E., Nanami, M., Kaneko, A., Yoshikubo, T. & Tsuchiya, M. (2005) A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. *Blood*, **105**, 562–566.

van den Oudenrijn, S., Bruin, M., de Haas, M. & von dem Borne, A.E. (2002) From gene to disease; from a thrombopoietin receptor gene defect to congenital amegakaryocytic thrombocytopenia. *Nederlands Tijdschrift voor Geneeskunde*, **146**, 469–471.

Pang, L., Weiss, M.J. & Poncz, M. (2005) Megakaryocyte biology and related disorders. *Journal of Clinical Investigation*, **115**, 3332–3338.

Pasquet, J.M., Gross, B.S., Gratacap, M.P., Quek, L., Pasquet, S., Payrastre, B., van Willigen, G., Mountford, J.C. & Watson, S.P. (2000) Thrombopoietin potentiates collagen receptor signaling in platelets through a phosphatidylinositol 3-kinase-dependent pathway. *Blood*, **95**, 3429–3434.

Patel, S.R., Hartwig, J.H. & Italiano, J.E. (2005) The biogenesis of platelets from megakaryocyte proplatelets. *Journal of Clinical Investigation*, **115**, 3348–3354.

Pick, M., Eldor, A., Grisaru, D., Zander, A.R., Shenhav, M. & Deutsch, V.R. (2002) Ex vivo expansion of megakaryocyte progenitors from cryopreserved umbilical cord blood. A potential source of megakaryocytes for transplantation. *Experimental Hematology*, **30**, 1079–1087.

Pick, M., Perry, C., Lapidot, T., Guimaraes-Sternberg, C., Naparstek, E., Deutsch, V. & Soreq, H. (2005) Stress-induced cholinergic signaling promotes inflammation-associated thrombopoiesis. *Blood*, **107**, 3397–3406.

Raslova, H., Komura, E., Le Couedic, J.P., Larbret, F., Debili, N., Feunteun, J., Danos, O., Albagli, O., Vainchenker, W. & Favier, R. (2004) FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. *Journal of Clinical Investigation*, **114**, 77–84.

Ravid, K., Lu, J., Zimmet, J.M. & Jones, M.R. (2002) Roads to polyploidy: the megakaryocyte example. *Journal of Cellular Physiology*, **190**, 7–20.

Rekhtman, N., Choe, K.S., Matushansky, I., Murray, S., Stopka, T. & Skoultchi, A.I. (2003) PU.1 and pRB interact and cooperate to repress GATA-1 and block erythroid differentiation. *Molecular and Cellular Biology*, **23**, 7460–7474.

Richardson, J.L., Shivdasani, R.A., Boers, C., Hartwig, J.H. & Italiano, Jr, J.E. (2005) Mechanisms of organelle transport and capture along proplatelets during platelet production. *Blood*, **106**, 4066–4075.

Roy, L., Coullin, P., Vitrat, N., Hellio, R., Debili, N., Weinstein, J., Bernheim, A. & Vainchenker, W. (2001) Asymmetrical segregation of chromosomes with a normal metaphase/anaphase checkpoint in polyploid megakaryocytes. *Blood*, **97**, 2238–2247.

Sandberg, M.L., Sutton, S.E., Pletcher, M.T., Wiltshire, T., Tarantino, L.M., Hogenesch, J.B. & Cooke, M.P. (2005) c-Myb and p300 reg-

ulate hematopoietic stem cell proliferation and differentiation. *Devlopmental Cell*, **8**, 153–166.

Scheding, S., Bergmann, M., Shimosaka, A., Wolff, P., Driessen, C., Rathke, G., Jaschonek, K., Brugger, W. & Kanz, L. (2002) Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. *Transfusion*, **42**, 321–327.

Schulze, H. & Shivdasani, R.A. (2004) Molecular mechanisms of megakaryocyte differentiation. *Seminars in Thrombosis and Hemostasis*, **30**, 389–398.

Schulze, H., Korpal, M., Bergmeier, W., Italiano, J.E. Jr, Wahl, S.M. & Shivdasani, R.A. (2004) Interactions between the megakaryocyte/platelet-specific beta1 tubulin and the secretory leukocyte protease inhibitor SLPI suggest a role for regulated proteolysis in platelet functions. *Blood*, **104**, 3949–3957.

Schuster, M.W., Beveridge, R., Frei-Lahr, D., Abboud, C.N., Cruickshank, S., Macri, M., Menchaca, D., Holden, J. & Waller, E.K. (2002) The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. *Experimental Hematology*, **30**, 1044–1050.

Shimizu, R., Ohneda, K., Engel, J.D., Trainor, C.D. & Yamamoto, M. (2004) Transgenic rescue of GATA-1-deficient mice with GATA-1 lacking a FOG-1 association site phenocopies patients with X-linked thrombocytopenia. *Blood*, **103**, 2560–2567.

Shiraga, M., Ritchie, A., Aidoudi, S., Baron, V., Wilcox, D., White, G., Ybarrondo, B., Murphy, G., Leavitt, A. & Shattil, S. (1999) Primary megakaryocytes reveal a role for transcription factor NF-E2 in integrin alpha IIb beta 3 signaling. *Journal of Cell Biology*, **147**, 1419–1430.

Shivdasani, R.A., Fujiwara, Y., McDevitt, M.A. & Orkin, S.H. (1997) A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. *EMBO Journal*, **16**, 3965–3973.

Slichter, S.J. (2004) Relationship between platelet count and bleeding risk in thrombocytopenic patients. *Transfusion Medicine Reviews*, **18**, 153–167.

Solberg, L.A. Jr (2005) Biologic aspects of thrombopoietins and the development of therapeutic agents. *Current Hematological Reports*, **4**, 423–428.

Stahl, C.P. & Zucker-Franklin, D. (1993) In vivo effects of interleukin-6 on thrombopoiesis. *Blood*, **81**, 2819–2820.

Steele, M., Hitzler, J., Doyle, J.J., Germeshausen, M., Fernandez, C.V., Yuille, K. & Dror, Y. (2005) Reduced intensity hematopoietic stem-cell transplantation across human leukocyte antigen barriers in a patient with congenital amegakaryocytic thrombocytopenia and monosomy 7. *Pediatric Blood Cancer*, **45**, 212–216.

Stepan, D.E., Sergis-Deavenport, E., Kelley, R., Christal J., Chen, C.F. & Nichol, J.L. (2005) Safety profile AMG531 in healthy volunteers and in thrombocytopenic patients with ITP. *Blood*, **106**, 1240a.

Sungaran, R., Markovic, B. & Chong, B.H. (1997) Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. *Blood*, **89**, 101–107.

Suzuki, K., Abe, M., Fukushima-Sugasawa, K., Shintani, M., Hirayama, F., Kawasaki, T., Hiramatsu, H. & Nakahata, T. (2005) YM477, a novel orally active thrombopoietin receptor agonist. *Blood*, **106**, 2298a.

Tavassoli, M. & Aoki, M. (1981) Migration of entire megakaryocytes through the marrow blood barrier. *British Journal of Haematology*, **48**, 25–29.

Tefferi, A. & Gilliland, D.G. (2005) The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. *Mayo Clinic Proceedings*, **80**, 947–958.

Tomer, A. (2002) Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. *Blood*, **99**, 1602–1609.

Tomer, A. (2004) Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2 N and 4 N) megakaryocytes. *Blood*, **104**, 2722–2727.

Tomer, A. & Harker, L.A. (1996) Measurements of in vivo megakaryocytopoiesis: studies in nonhuman primates and patients. *Stem Cells*, **14** (Suppl. 1), 18–30.

Tomer, A., Harker, L.A. & Burstein, S.A. (1987) Purification of human megakaryocytes by fluorescence-activated cell sorting. *Blood*, **70**, 1735–1742.

Tomer, A., Harker, L.A. & Burstein, S.A. (1988) Flow cytometric analysis of normal human megakaryocytes. *Blood*, **71**, 1244–1252.

Tomer, A., Friese, P., Conklin, R., Bales, W., Archer, L., Harker, L.A. & Burstein, S.A. (1989) Flow cytometric analysis of megakaryocytes from patients with abnormal platelet counts. *Blood*, **74**, 594–601.

Tsang, A.P., Visvader, J.E., Turner, C.A., Fujiwara, Y., Yu, C., Weiss, M.J., Crossley, M. & Orkin, S.H. (1997) FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. *Cell*, **90**, 109–119.

Vadhan-Raj, S., Cohen, V. & Bueso-Ramos, C. (2005) Thrombopoietic growth factors and cytokines. *Current Hematological Reports*, **4**, 137–144.

Van Os, E., Wu, Y.P., Pouwels, J.G., Ijsseldijk, M.J., Sixma, J.J., Akkerman, J.W., De Groot, P.G. & Van Willigen, G. (2003) Thrombopoietin increases platelet adhesion under flow and decreases rolling. *British Journal of Haematology*, **121**, 482–490.

Wang, J.F., Liu, Z.Y. & Groopman, J.E. (1998) The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. *Blood*, **92**, 756–764.

Wolanskyj, A.P., Lasho, T.L., Schwager, S.M., McClure, R.F., Wadleigh, M., Lee, S.J., Gilliland, D.G. & Tefferi, A. (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. *British Journal of Haematology*, **131**, 208–213.

Wolber, E.M., Fandrey, J., Frackowski, U. & Jelkmann, W. (2001) Hepatic thrombopoietin mRNA is increased in acute inflammation. *Thrombosis and Haemostasis*, **86**, 1421–1424.

Yamamoto, K., Nagata, K., Tsurukubo, Y., Morishita, K. & Hamaguchi, H. (2000) A novel translocation t(3;22)(q21;q11) involving 3q21 in myelodysplastic syndrome-derived overt leukemia with thrombocytosis. *Leukemia Research*, **24**, 453–457.

Zauli, G. & Catani, L. (1995) Human megakaryocyte biology and pathophysiology. *Critical Reviews in Oncology/hematology*, **21**, 135–157.

Zhang, Y., Nagata, Y., Yu, G., Nguyen, H.G., Jones, M.R., Toselli, P., Jackson, C.W., Tatsuka, M., Todokoro, K. & Ravid, K. (2004) Aberrant quantity and localization of Aurora-B/AIM-1 and survivin during megakaryocyte polyploidization and the consequences of Aurora-B/AIM-1-deregulated expression. *Blood*, **103**, 3717–3726.

Zucker-Franklin, D. (1970) The submembranous fibrils of human blood platelets. *Journal of Cell Biology*, **47**, 293–299.

Zucker-Franklin, D. & Petursson, S. (1984) Thrombocytopoiesis – analysis by membrane tracer and freeze-fracture studies on fresh human and cultured mouse megakaryocytes. *Journal of Cell Biology*, **99**, 390–402.

Zucker-Franklin, D. & Philipp, C.S. (2000) Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept. *American Journal of Pathology*, **157**, 69–74.